Table 1 Phase 3 trial results, to date, of anti-angiogenic agents in the treatment of advanced breast cancer
From: Angiogenesis - still a worthwhile target for breast cancer therapy?
Trial name and design | Treatment type | Progression free survival (months)a | Overall survival (months)a | Response ratea |
|---|---|---|---|---|
Capecitabine ± bevacizumab | Refractory | 4.86 versus 4.17 (HR 0.98; P = 0.857) | 15.1 versus 14.5 | 19.8% versus 9.1% (P = 0.001) |
RIBBON-2: second line chemotherapy ± bevacizumab | Second line | 7.2 versus 5.1 (HR 0.775; P = 0.0072) | 18.0 versus 16.4 (P = 0.372) | 39.5% versus 29.6% (P = 0.0193) |
E2100: paclitaxel ± bevacizumab | First line | 11.8 versus 5.9 (HR 0.60; P = <0.001) | 26.7 versus 25.2 (HR 0.88; P = 0.16) | 36.9% versus 21.2% (P < 0.001) |
AVADO: docetaxel ± bevacizumab | First line | 8.8 versus 8.0 (HR 0.61; P = 0.0001) | Not published | 44.4% versus 63.1% (P = 0.0001) |
RIBBON-1: capecitabine (C) or taxane (T) or anthracycline (A) ± bevacizumab or placebo | Second line | C: 8.6 versus 5.7 (HR 0.688; P = 0.0002) A + Tb: 9.2 versus 8.0 (HR 0.644; P ≤ 0.0001) | C: 29.0 versus 21.2 (HR 0.847; P = 0.2706) A + Tb: 25.2 versus 23.8 (HR 1.032; P = 0.8298) | C: 35.4% versus 23.6% (P = 0.0097) A + Tb: 51.3% versus 37.9% (P = 0.0054) |
Capecitabine ± sunitinib | Refractory | 5.5 versus 5.9 (HR 1.224) | 16.4 versus 16.5 (HR 0.995) | 18.6% versus 16.3% |
Capecitabine versus sunitinib | Refractory | 2.8 versus 4.2 (HR 1.473; P < 0.001) | Not published | 9.1% versus 12.9% |
Docetaxel ± sunitinib | First line | 8.6 versus 8.3 (HR 0.922) | 24.8 versus 25.5 (HR 1.207) | 51% versus 39% (P = 0.0018) |